Мета-аналитический подход в изучении антигипертензивной эффективности индапамида с контролируемым высвобождением в терапии больных с артериальной гипертензией (по данным открытых исследований)
Abstract The paper presents a meta-analysis of open-label antihypertensive effectiveness studies of indapamide SR (Arifon Retard, Servier Laboratories, France) in hypertensives. 24 Russian (n = 4952) and 4 foreign (n = 4634) studies were included in analysis. Russian studies show that indapamide retard both as a monotherapy and a component of the combination therapy leads to a 17,8/14,0 % decrease of systolic/diastolic blood pressure that is a reduction for 29.2 (95 % CI 28,9–29,5)/12,3 (12,1–12,5) mmHg in patients with uncontrolled hypertension. Baseline blood pressure was the main predictor of its reduction, and the most signifi cant reduction for 32,6 (95 % CI 25,5–39,6) mmHg was seen when the average baseline systolic blood pressure exceeded 170 mmHg. Antihypertensive effi cacy of indapamide retard was similar in Russian and foreign studies. However, incidence of therapy-related side effects was higher in Russian studies than in foreign ones (5,9 and 3,3 % respectively, p < 0,001). Therefore, meta-analysis based on the data of open Russian studies confi rms the antihypertensive effectiveness of indapamide retard and demonstrates the comparability of the results to those found in multicenter foreign studies.